Skip to search formSkip to main contentSkip to account menu

Ethyol

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Amifostine (Ethyol®) is a cytoprotective drug approved for the reduction of xerostomia in head and neck cancer when administered… 
Highly Cited
2002
Highly Cited
2002
Amifostine (Ethyol) has been evaluated clinically as a radioprotective agent for the prevention of xerostomia and mucositis for… 
Highly Cited
2001
Highly Cited
2001
Oxaliplatin, a third-generation platinum compound with a 1,2-diaminocyclohexane (DACH) carrier ligand, is a recently developed… 
Highly Cited
2000
Highly Cited
2000
Purpose: Amifostine (WR-2721), a phosphorylated aminothiol pro-drug which is an analogue of cysteamine, is a selective… 
Highly Cited
2000
Highly Cited
1997
Highly Cited
1997
The main metabolites of the cytoprotective drug Ethyol (Amifostine, WR-2721) are the thiol WR-1065 and the disulphide WR-33278… 
Review
1994
Review
1994
Amifostine (WR-2721, S-2 [3-aminopropylamino]-ethylphosphorothioic acid; Ethyol, US Bioscience, Inc. West Conshohocken, PA… 
Highly Cited
1994
Highly Cited
1994
This study investigated the metabolism of the radio- and chemoprotector compound, WR-2721 [amifostine; s-2-(3- aminopropylamino… 
Review
1994
Review
1994
Radiotherapeutic studies with amifostine (WR-2721; Ethyol, US Bioscience, Inc, West Conshohocken, PA) are reviewed, with evidence… 
Review
1994
Review
1994
  • R. Capizzi
  • Seminars in Oncology
  • 1994
  • Corpus ID: 43759659
The rationale for the clinical trials with amifostine (Ethyol, US Bioscience, Inc, West Conshohocken, PA) is based on an…